A Case Report of Pregnancy Complicated with Primary Hemophagocytic Lymphohistiocytosis
DOI: https://doi.org/10.2147/ijwh.s460352
2024-05-18
International Journal of Women s Health
Abstract:Yan Chen, &ast Xiaohuan Huang, &ast Hongfei Chen, Junru Tong, Lingling Huang, Junyou Su, Li Deng Department of Obstetrics, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530007, People's Republic of China &astThese authors contributed equally to this work Correspondence: Li Deng; Junyou Su, Email ; Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by excessive activation of NK cells and cytotoxic T lymphocytes, subsequently leading to macrophage activation and increased cytokine production. Misdiagnosis due to nonspecific clinical presentations and inadequate understanding of the disease can significantly jeopardize the safety of both the mother and the infant. We report a case of pregnancy combined with HLH and conduct a literature review to provide insights into the diagnosis and treatment of pregnancy-related HLH. Case Presentation: We discussed a case of a pregnant woman with persistent postpartum fever, serum ferritin, and elevated liver function, who failed to respond to repeated anti-infective therapy and was diagnosed with HLH after multidisciplinary diagnostic treatment. We gave dexamethasone treatment, and the patient's temperature and blood cells quickly returned to normal. Finally, exome sequencing revealed heterozygous variation in UNC13D gene, so we considered this case as pregnancy combined with primary HLH (pHLH). Conclusion: We report the case of HLH diagnosed during pregnancy and show that early diagnosis and timely intervention can prevent rapid disease progression, reduce maternal mortality rates, and improve survival rates. Additionally, molecular genetic testing can confirm pathogenic gene mutations, providing essential genetic counseling for patients with pHLH who plan to conceive a healthy child. Keywords: hemophagocytic lymphohistiocytosis, hemophagocytic syndrome, pregnancy, case report Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome (HPS), is a severe hyperinflammatory syndrome characterized by excessive activation of NK cells and cytotoxic T lymphocytes, subsequently leading to macrophage activation and increased cytokine production. While there are two types of HLH—primary and secondary—based on whether a specific genetic abnormality linked to HLH exists, growing research characterizes HLH as a more complicated condition that arises from particular immune challenges in patients with a susceptible genetic background. 1 Primary (pHLH), which includes familial HLH (FHL), immune deficiency syndrome-associated HLH, and Epstein-Barr virus (EBV)-driven HLH, is an autosomal or sex chromosomal recessive disorder that often occurs in childhood. 2 Secondary (sHLH) is often induced by infections (viral, bacterial, fungal, or other), autoimmune diseases, malignancies, drugs and other risk factors, and there is usually no known genetic defect causing HLH and no family history of it. 3 However, the complicated reality of genetic causality in HLH is oversimplified by this dichotom. 4 For instance, the distinction between sHLH and pHLH has become obscure due to the ongoing advancements in the detection and comprehension of gene mutations, and it is also thought that sHLH has a specific genetic background. 5 Moreover, placing nearly all non-FHL patients under sHLH suggests an unjustified similarity in etiology and therapy, which could result in ineffective or inappropriate care. 6 With the deepening of molecular genetics research, some primary immunodeficiency disorders (PID) and inborn metabolic defects are susceptible to HLH, and new candidate genes for pHLH are gradually expanding. 3 In addition, after suffering from external triggers (such as viral infection, etc.) after the "second blow" showed HLH onset. HLH has a worldwide annual incidence of 1 in 800,000, with a high mortality rate of up to 40%. Untreated HLH has a median survival time of no more than two months. 6,7 Currently, the majority of reported cases of pregnancy-associated HLH both in China and internationally are sHLH, whereas research on pregnancy-associated pHLH remains limited. Misdiagnosis due to nonspecific clinical presentations and inadequate understanding of the disease can significantly jeopardize the safety of both the mother and the infant. This report presents a case of pregnancy-associated pHLH, which was successfully treated at the Second Affiliated Hospital of Guangxi Medical University. In addition, we conducted literature review to provide insights into the diagnosis and treatment of pregnancy-associated HLH. This case report has been approved by the Medical Ethics Committee of the Second Affiliated -Abstract Truncated-
obstetrics & gynecology